These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16613576)

  • 1. Ifosfamide. Metabolic studies, new therapeutic approaches and new analogs.
    Misiura K
    Mini Rev Med Chem; 2006 Apr; 6(4):395-400. PubMed ID: 16613576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
    Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
    Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
    Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
    J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide nephrotoxicity in pediatric cancer patients.
    Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
    Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
    Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
    Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
    Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
    Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
    Lokiec F
    Ann Oncol; 2006 May; 17 Suppl 4():iv33-6. PubMed ID: 16702183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
    Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
    Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question.
    Williams ML; Wainer IW
    Curr Pharm Des; 1999 Aug; 5(8):665-72. PubMed ID: 10469897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
    Sloderbach A; Górska A; Sikorska M; Misiura K; Hładoń B
    Postepy Hig Med Dosw (Online); 2013 Dec; 67():1235-53. PubMed ID: 24379264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing ifosfamide in innovative treatment modalities.
    Dittrich C
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S1-3. PubMed ID: 12042981
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial measurements of ifosfamide and cyclophosphamide in patients using (31)P MRS: pulse-and-acquire, decoupling, and polarization transfer.
    Payne GS; Pinkerton CR; Bouffet E; Leach MO
    Magn Reson Med; 2000 Aug; 44(2):180-4. PubMed ID: 10918315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
    Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
    Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and pharmacokinetics of oxazaphosphorines.
    Boddy AV; Yule SM
    Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermal enhancement of the effect of ifosfamide against a spontaneous murine fibrosarcoma, FSa-II.
    Kuroda M; Urano M; Reynolds R
    Int J Hyperthermia; 1997; 13(1):125-31. PubMed ID: 9024933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
    Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
    Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the clinical pharmacokinetics of trofosfamide.
    Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
    Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas.
    Lopez M; Carpano S; Amodio A; Gionfra T; Della Giulia M; Foggi P; Manfredi C; Del Monte G
    Clin Ter; 1998; 149(5):331-3. PubMed ID: 10052244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.